Test Discontinuation Memorandum

This memo is to inform you that the Medical Genetics Laboratories will discontinue the JAK2 R683 Mutation Analysis test effective February 20, 2014. We will continue to offer an extensive menu of cancer genetic tests including JAK2 V617F (Test Code 9010) and JAK2 Exon 12 (Test Code 9015) mutation analyses. We also offer a Myeloproliferative Neoplasia Panel that includes JAK2 V617F, JAK2 Exon 12, and MPL Exon 10 mutation analyses (Test Code 9050).

Previous Post
Test Change Memorandum
Next Post
Test Change Memorandum